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INTRODUCTION
Epigenetics may be broadly defined as the study of processes that produce a heritable phenotype
that is not strictly dependent on DNA sequence. The definition has traditionally been restricted
to processes that occur in the cell's nucleus, with the term “heritable” having a loose meaning
that can be applied to either the entire organism or single cells. For example, a process that
produces a phenotype only in a specific cell type (for instance, chromatin-mediated
maintenance of a differentiated state) is usually considered epigenetic even if it is not directly
inherited, but instead must be reestablished or actively maintained at each cell division. Given
this definition, the field of epigenetics has long focused on proteins that affect DNA packaging,
and thereby affect the utilization of the genetic information encoded in the DNA template. This
focus extends to the enzymatic modification of those proteins, and to the enzymatic
modification of the DNA template itself, primarily DNA methylation.
This review is written in conjunction with the international symposium on Genome-wide
Epigenetics 2005, held at the University of Tokyo, Japan on November 8–10, 2005. Over the
past decade, the field of epigenetics has undergone an exciting expansion in the number of
researchers, techniques available and our understanding of epigenetic phenomena. The purpose
of this short review is not to summarize all of these advances, but rather to guide the reader to
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more detailed sources of information by sketching an outline of the major thrusts in the field,
emphasizing mammalian epigenetics in particular.
MEDIATORS OF EPIGENETIC REGULATION OF THE GENOME
Epigenetic information manifests itself by regulating gene expression. The mechanistic
mediators of heritable gene expression appear to be similar whether one is considering
epigenetic inheritance on the organismal or cellular level. For example, a mediator of epigenetic
regulation is cytosine methylation. The action of maintenance methyltransferases ensures that
the methylation of pairs of cytosines on complementary DNA strands at CpG dinucleotides is
propagated to both pairs of daughter DNA molecules following DNA replication (Bestor
2000). The inheritance of gene regulatory information from parental gametes defines the
phenomenon of genomic imprinting, for which cytosine methylation is a central mediator (Li
et al. 1993).
Cytosine methylation is the best-studied mediator of epigenetic regulation. In mammalian
genomes, the vast majority of methylation of cytosines occurs when the cytosine is followed
by a guanine, a so-called CpG dinucleotide (Clark et al. 1995). The methyl group protrudes
into the major groove of the DNA double helix, preventing the binding of transcription factors
that would otherwise bind locally in a sequence-specific manner (Bell and Felsenfeld 2000;
Hark et al. 2000), and facilitating the binding of methyl-binding proteins that generally attach
to DNA in a sequence non-specific manner (Jorgensen and Bird 2002). The methylation of
cytosines may not be the initiating event in a change from activity to silencing of a locus, but
it is certainly associated with a number of events including the alteration of covalent
modifications of histone tails (El-Osta and Wolffe 2000), the recruitment of methyl-binding
proteins (Jorgensen and Bird 2002) and proteins normally associated with distinctive chromatin
states (such as SWI/SNF components (Harikrishnan et al. 2005)), and the compaction of the
chromatin with silencing of gene expression locally (Nguyen et al. 2001).
It is possible that cytosine methylation is induced by primary events involving the covalent
modification of histone tails. The histone octamers that form the nucleosome protrude N-
terminal tails, where it was thought that various combinations of methylation, acetylation,
phosphorylation and other post-translational modifications could be established to create what
has been referred to as the histone code (Jenuwein and Allis 2001). However, this combinatorial
concept is being challenged by data suggesting that the pattern of modifications may be more
simple than the potential complexity, establishing what is more like a binary on or off pattern
(Dion et al. 2005; Liu et al. 2005a; Schubeler et al. 2004). As described for methylcytosine,
these modified histone molecules are capable of recruiting further molecules and complexes
that influence chromatin structure and local gene activity. Whether histone tail modifications
induce or are induced by cytosine methylation, it seems that the disruption of one component
of this system can induce changes in other components also (Ben-Porath and Cedar 2001).
The recent finding in fission yeast that small RNAs are targeted to heterochromatin (Verdel et
al. 2004) suggests that epigenetic gene regulation in mammalian cells may also involve the
actions of such short RNAs. In addition, it has been observed that a subset of DNA
methyltransferases and methyl-binding proteins have RNA-binding properties (Jeffery and
Nakielny 2004), supporting the idea that RNA molecules may influence the regulation of
expression of their own or other loci. However, a point worth stressing is that the major
consequence of all these biochemical processes, which ultimately alter gene expression, is the
regulation of transcription factor binding. Transcription factors bind in modules at specific loci
to facilitate the loading of the RNA polymerase complex locally, a prerequisite for gene
expression. The relationship between epigenetic regulation and transcription-factor binding
tends to be overlooked in reviews of either field. However, as we emphasize below, techniques
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to study chromatin components and transcription factors in vivo are equally advanced, allowing
integration of data and major advances in the understanding of the relationship of epigenetic
alterations with transcription factor binding. An example of such a study shows a relationship
between binding of the CTCF transcription factor and cytosine methylation genome-wide
(Mukhopadhyay et al. 2004). The use of high-throughput techniques to study epigenetic
regulatory processes in large genomic regions or genome-wide has been described as an
‘epigenomic’ approach (Fazzari and Greally 2004). Our insights into epigenetic regulatory
processes have to date been founded mostly on detailed studies of individual loci; now that
epigenomic approaches have been developed, we are beginning to accrue knowledge based on
less detailed studies of large numbers of loci.
DÉJÀ VU: WHY STUDY THE WHOLE EPIGENOME?
Although many of the details remain unclear, few people today doubt the importance of
epigenetic processes (in addition to the genetic code) for biological and medical research. A
full understanding of epigenetic inheritance and how epigenetic regulatory information is
distributed in the genome therefore ought to be the ultimate aim of any genome-wide
epigenetics or Epigenome Project. Of course, there is currently much debate on whether the
time and technology is ready for such an enormous undertaking and those who remember the
early discussions about the Human Genome Project will find some of the arguments
reminiscent of that time. For the Genome Project, the turning point came in 1995, when the
more pragmatic protagonists at the time pointed out that a (draft) genome sequence could be
generated with existing technology (Marshall 1995). Anticipating, of course, that the effort
would be self-catalyzing once started which, with the luxury of hindsight, turned out to be true
when the Human Genome was announced finished in 2003, under budget and ahead of time.
Exactly when the discussion about the Epigenome Project started is arguable, most likely it
started independently in the minds of multiple scientists. In Pubmed, the first indexed
mentioning of ‘Epigenome’ appeared in 1987 (Kieser 1987) and ‘Epigenome Project’ was
mentioned the first time only in 2002 (Novik et al. 2002). Therefore, a 'spoof' editorial in a
leading science magazine (Nature Biotechnology) was quite timely when it suggested in August
2000 that a trilogy be required to complete the Human Genome Project: “The Draft”, “The
Closure” and “Epigenetics Strikes Back”. With the “Draft” and the “Closure” delivered, the
time has come to explore the next frontier, the “Epigenome”.
The rationale for studying the epigenome and how this might be accomplished has been
reviewed recently (Murrell et al. 2005). Basically, different cell types require different
epigenomes to control – in time and space - the correct execution of their individual
transcriptional programs and (reversible) epigenetic modulation has the flexibility to achieve
the required fine-tuning of the underlying nuclear genome. A recent study further suggests that
the transcriptional program is much larger and more complex than previously thought (Cheng
et al. 2005). High-resolution transcript mapping of 10 human chromosomes revealed that the
majority of (mostly non-polyadenylated) transcripts map to loci for which there is currently
no annotation available. Yet, these transcripts of unknown function may have important
implications for gene expression and (epi)genotype-phenotype associations. The power to
detect any alterations anywhere in the epigenome will therefore be of great value to understand
what goes wrong if a program is executed incorrectly, particularly in the context of disease.
Obviously, our ability to analyze and interpret entire epigenomes is very much dependent upon
the availability of adequate technologies which will be discussed in the next section.
TECHNIQUES FOR GENOME-WIDE EPIGENETIC STUDIES
Much of the recent progress in understanding epigenetic phenomena is directly attributable to
technologies that allow researchers to pinpoint the genomic location of proteins that package
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and regulate access to the DNA. The advent of DNA microarrays and inexpensive DNA
sequencing has allowed many of those technologies to be applied to the whole genome. The
focus of the Tokyo conference is the study of epigenetics on a genome-wide scale, so here we
will focus on technologies that enable a comprehensive investigation of the genome. We note
that Bas van Steensel's group has recently published a series of very informative reviews
relevant to this subject (Loden and van Steensel 2005; van Leeuwen and van Steensel 2005;
van Steensel 2005).
Genome-wide cytosine methylation studies
Cytosine methylation has been the best-studied epigenetic mechanism, largely because the
experimental techniques for its study have been available for some time. The mainstays of
experimental approaches have been the sensitivity of certain restriction enzymes to cytosine
methylation and the relative resistance of methylcytosine to bisulfite-induced deamination.
Experiments based on these approaches have revealed great detail about individual loci. The
expansion of these studies from single-locus to genome-wide approaches is still in
development. A platform that has proven to be very robust is that using restriction landmark
genome scanning (RLGS), which uses a rare-cutting methylation-sensitive restriction enzyme
(such as NotI) in combination with a second enzyme to create a profile of NotI digestion
products. The digested NotI overhanging ends are radiolabeled and separated by 2-dimensional
gel electrophoresis. Approximately 2,000 sites can be resolved using RLGS. Using virtual
image RLGS (vi-RLGS), the actual pattern of NotI fragments can be compared with the
computationally predicted pattern for that genome (Matsuyama et al. 2003). This allows
differences observed by gel electrophoresis to be linked to specific genomic locations for
subsequent validation studies. The technique suffers from being technically challenging,
difficult to validate even with vi-RLGS, and limited in terms of the number of loci that are
testable (Fazzari and Greally 2004). Nonetheless, it has been the single most informative
technique describing differences in cytosine methylation between tissues, stages of
differentiation and in disease (Kremenskoy et al. 2003; Shiota et al. 2002; Song et al. 2005).
Other restriction enzyme-based techniques have also been developed, and high-throughput
bisulfite sequencing using MALDI-TOF looking at numerous loci in parallel has been the
foundation of the European Human Epigenome Project (Bradbury 2003; Rakyan et al. 2004).
Most of the techniques used to date have been reviewed comprehensively (Laird 2003;
Ushijima 2005), although several recent publications update this list (Ching et al. 2005; Hu et
al. 2005; Weber et al. 2005). The techniques differ in terms of how they select a fraction of the
genome with distinctive cytosine methylation. Most use the sensitivity of restriction enzymes
to cytosine methylation as the means of discrimination, while a new technique uses the affinity
of an anti-methylcytosine antibody to enrich the methylated fraction of the genome (methylated
DNA immunoprecipitation, MeDIP (Weber et al. 2005)). The techniques also differ in terms
of how they detect the genomic source of these distinctive fractions, with gel electrophoresis
now largely superseded by microarray-based approaches or high-throughput sequencing.
At present, there is no technique that can test the methylation status of every CpG dinucleotide
in the genome. Furthermore, little attention has been paid to the effects of the heterogeneity of
CpG dinucleotide clustering in the genome, apart from using this property to define CpG islands
(Gardiner-Garden and Frommer 1987; Takai and Jones 2002). Clustering of CpGs increases
the number of informative cytosines or restriction sites in some areas compared with others,
so that a comparison of cytosine methylation genome-wide will show much stronger signals
of methylation or the absence of methylation at sites of clustering than sites where CpGs are
relatively more sparse. Possible because of this, our attention is focused on CpG-enriched
regions as particularly informative. Our appreciation of the role of less CpG-rich regions in
dynamic methylation patterns remains limited as a consequence.
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The “ChIP-chip” method is currently the most popular technique for high-resolution mapping
of chromatin proteins and enzymes. ChIP-chip, which combines chromatin
immunoprecipitation (ChIP) and microarray analysis (chip), was developed in the late 1990s
(Nature Genetics editorial 1998) and first published shortly thereafter (Iyer et al. 2001; Ren et
al. 2000). Generally, cells are fixed, chromatin is fragmented, and the protein of interest is
purified, along with any associated DNA, using an antibody or an affinity tag. The DNA that
was co-purified with the protein is then detected using a DNA microarray and mapped back
to the genome, allowing the binding position of the protein to be inferred. The details of this
technique have been reviewed extensively (Bernstein et al. 2004a; Buck and Lieb 2004;
Farnham 2002; Hanlon and Lieb 2004; Im et al. 2004; Johnson and Bresnick 2002; Kuo and
Allis 1999; Kurdistani and Grunstein 2003; Lieb 2003; Nal et al. 2001; Oberley and Farnham
2003; Oberley et al. 2004; Orlando 2000; Robyr et al. 2004; Spencer et al. 2003; Weinmann
and Farnham 2002). Initial ChIP-chip studies focused on the genome-wide location of well-
studied yeast transcription factors. These studies empirically verified the effectiveness of the
method by identification of previously known gene targets, and discovery of new and
physiologically relevant targets (Horak and Snyder 2002; Iyer et al. 2001; Lieb et al. 2001;
Ren et al. 2000; Simon et al. 2001). In addition, DNA-binding motifs corresponding to the
known affinities of the proteins were derived from the ChIP-chip data. In the short time since
those original studies, ChIP-chip has been applied to hundreds of transcription factors in
organisms ranging from bacteria to humans (van Steensel 2005).
Mapping the genomic location of chromatin proteins and enzymes by ChIP-chip
Chromatin components and determinants of chromatin dynamics are often the mediators of
epigenetic effects. The genome-wide mapping of these chromatin marks by ChIPchip has led
to important insights regarding the mechanism of transcriptional and epigenetic memory, and
how different chromatin states are propagated through the genome. In yeast, ChIP-chip has
been used to determine the distribution of non-histone chromatin components (Glynn et al.
2004; Lengronne et al. 2004; Smith et al. 2003; Weber et al. 2004), enzymes involved in histone
modification (Humphrey et al. 2004; Kurdistani et al. 2002; Ng et al. 2003), and post-
translational histone modifications themselves (Bernstein et al. 2002; Kurdistani et al. 2004;
Loden and van Steensel 2005; Robyr et al. 2002; van Leeuwen and van Steensel 2005).
More recently, the approach of assessing global chromatin structure has been extended to more
complex genomes. In Drosophila, the global acetylation pattern of histones H3 and H4 and the
global methylation pattern of histone H3 lysine 4 (H3K4) and lysine 79 (H3K79) have been
monitored using ChIP-chip (Schubeler et al. 2004). H3K4 di- and trimethylation, H3K79
dimethylation and H3 and H4 acetylation were all found to be present in the same genes. These
results are in agreement with the genome-wide pattern of H3K4 methylation (Bernstein et al.
2002) and Set1p binding (Ng et al. 2003) in yeast and suggest that, in Drosophila, as in yeast,
a pattern of nucleosome modifications distinguishes actively transcribed genes from repressed
genes throughout the genome. Detailed genome-scale studies have also been carried out in
Arabidopsis (Lippman et al. 2004).
Although the antibodies used for ChIP-chip studies of chromatin modifications can often be
used across species, as of the printer's deadline there no published reports of genome-wide,
high-resolution chromatin modification ChIP-chips in mammalian cells. This is mainly due to
difficulty in producing inexpensive and easy-to-use full-genome microarrays. The initial
mammalian ChIP-chip experiments identified binding sites for the c-Myc, Max, Gata1, E2F
and Rb transcription factors in cultured human cells (Horak et al. 2002; Li et al. 2003;
Weinmann et al. 2002; Wells et al. 2003). By practical necessity, the DNA microarrays used
in these pioneering studies represented only a fraction of the genome. For the c-Myc and Max
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studies, DNA microarrays were constructed with PCR products spanning the proximal
promoters of 4,839 of the approximately 30,000 human genes (Li et al. 2003). Later studies
that examined the genomic distribution of the mammalian Set1 homolog MLL used an
expanded version of this array that included 19,000 proximal promoters (Guenther et al.
2005). To map the mammalian transcription factors E2F and Rb, DNA microarrays were
created with 7776 CpG island clones (Weinmann et al. 2002; Wells et al. 2003). CpG islands
are short stretches of DNA containing a high density of non-methylated CpG dinucleotides,
and are associated with the promoters and the first exon of a gene (Antequera and Bird
1993). Studies of transcription factor binding across human chromosomes 21 and 22 have been
carried out (Carroll et al. 2005; Cawley et al. 2004; Euskirchen et al. 2004; Martone et al.
2003). These chromosome 21 and 22 arrays were also used for the first genome-scale study of
histone modifications (H3K4me2, H3K4me3, and H3K9/14Ac) in human cells (Bernstein et
al. 2005). This year a group of researchers published the first truly genomic human ChIP-chip
experiment, using an array of 14.5 million 50mers that covered the unique regions of the human
genome at 100 bp resolution to analyze the distribution of TFIID on the human genome (Kim
et al. 2005b). Microarrays similar to the one used in that study are in commercial development,
and many chromatin modifications are being mapped as part of the NIH's ENCODE project
(2004; Boguski 2004; van Steensel 2005).
There are some challenges inherent to any ChIP-chip experiment, and experiments that aim to
determine the distribution of chromatin components and histone modifications are especially
subject to these concerns. Several factors could create non-biological variation in results,
including the effects of fixation, epitope accessibility, antibody specificity, microarray content,
and underlying bulk nucleosome occupancy. These challenges, and suggestions for
overcoming them, have been discussed at length in recent reviews (Buck and Lieb 2004;
Hanlon and Lieb 2004; Loden and van Steensel 2005; van Leeuwen and van Steensel 2005).
ChIP-chip alternatives: Dam-ID and in vivo biotin-tagging
Current alternatives to ChIP-chip include the use of DNA adenine methyltransferase-
Identification (Dam-ID) (Greil et al. 2003; van Steensel et al. 2001; van Steensel and Henikoff
2003, 2000). In this method, the eukaryotic chromatin protein of interest is fused with the
bacterial enzyme DNA adenine methyltransferase. Any DNA with which the protein is
associated will then be methylated at adenine, a mark normally restricted to prokaryotes. The
methylated DNA can then be purified with antibodies or probed with methyl-sensitive
restriction enzymes to deduce the location of the protein's interaction with genomic DNA. The
Dam-ID is very powerful because it does not require antibodies to be raised against each factor
of interest and obviates the need for crosslinking. However, it requires expression of a
recombinant protein, careful control of the level and duration of expression, and cannot be used
to map post-translational histone modifications. A second technique requires that the chromatin
component be tagged with the biotin ligase recognition peptide, and that this fusion protein
and biotin ligase be co-expressed in the same cell type. Cellular biotin is conjugated to the
chromatin protein of interest, allowing streptavidin to be used on sheared chromatin from these
cells to isolate the DNA at which this chromatin component is located. This approach has been
used to track histone H3.3 localization in cultured Drosophila cells (Mito et al. 2005).
Genome-wide in vitro methods to determine DNA-binding specificity and quantify the
influence of epigenetic processes
Many epigenetic effects are mediated, ultimately, through their effect on transcription factors
and transcriptional regulation. To understand how epigenetic processes influence
transcriptional programs, accurate binding-site descriptions of hundreds of transcription factors
will likely be needed. DNA-binding specificity can be determined by many well-established
methods, including binding site selection (SELEX) (Oliphant et al. 1989; Tuerk and Gold
Lieb et al. Page 6













1990) and electrophoretic mobility shift assays (EMSA) (Fried and Crothers 1981). However,
these methods are labor-intensive, not amenable to high-throughput analysis, and do not sample
the full range of a protein’s natural in vivo DNA substrates. As described below, one can use
ChIP-chip experiments to infer binding motifs from computational analysis of the ChIP-
enriched sequences (Liu et al. 2002). While ChIP-chip is a powerful method, the ability to infer
relevant and accurate binding sites is dependent on a number of factors, including adequate
expression of the protein of interest, nuclear localization and DNA binding by that protein, and
availability of a specific antibody that is capable of recognizing the protein in the context of a
specific DNA-protein complex. Furthermore, the discovery of binding sites from ChIP-chip
data is complicated by the effects of protein-protein interactions, and the cooperative and
competitive DNA binding of other proteins in vivo. Two high-throughput in vitro methods for
the determination of DNA-binding specificity have emerged recently: Protein Binding
Microarrays (PBMs) (Mukherjee et al. 2004) and DIP-chip (DNA ImmunoPrecipitation
followed by microarray analysis) (Liu et al. 2005b).
In the PBM approach, a purified, epitope-tagged DNA binding protein is incubated with a
microarray spotted with double-stranded DNA corresponding either to short, synthetic double-
stranded oligonucleotides (Bulyk et al. 2001; Mukherjee et al. 2004) or longer PCR products
(Mukherjee et al. 2004). The protein-bound microarray is then washed gently and stained with
a fluorophore-conjugated anti-tag antibody (for example, an anti-GST antibody would be used
with GST-tagged protein); alternatively, a fluorophore-conjugated anti- transcription factor
primary antibody could be used. The stained array is then washed, spun dry, and scanned with
a standard microarray scanner. The PBM experimental protocol takes less than a day, and
multiple PBM microarray experiments can be performed in parallel. The PBM data, normalized
by DNA concentration, are analyzed with a motif finding algorithm in order to identify the
protein’s DNA binding sites. Although PBM experiments can be performed using some
‘standard’ binding conditions, one could examine the effects of altered binding conditions,
such as alterations in buffer composition, transcription factor concentration, or even the effects
of small molecule or protein cofactors. Importantly, the PBM experiments do not require prior
knowledge of the culture conditions in which the transcription factor is expressed, do not
require potentially limiting tissue sources, and do not require protein-specific antibodies.
Comparison of PBM and ChIP-chip data has revealed that the respective DNA binding site
motifs can correspond quite well (Mukherjee et al. 2004). Moreover, comparison of the in
vivo and in vitro binding data will permit an analysis of what local sequence context features
may contribute to binding site usage. PBM data will be useful for generating binding site motifs
for known and predicted transcription factors with poorly or uncharacterized DNA binding
specificities. Such binding site data, coupled with further computational analyses, will permit
the prediction of the regulatory roles of transcription factors, as well as the prediction of
candidate cis regulatory modules (i.e., transcriptional enhancers) (Bulyk 2003; Philippakis et
al.; Philippakis et al. 2005).
In DIP-chip, a purified DNA binding protein is incubated with purified, sheared yeast genomic
DNA. Protein-DNA complexes are separated from unbound DNA using immunoprecipitation
or affinity purification. Purified DNA fragments are amplified, labeled fluorescently, and
identified by hybridization to a DNA microarray. Computational methods are then used to
define a binding site based on enriched sequences. DIP-chip, while similar in concept to ChIP-
chip, can overcome some of the limitations of ChIP-chip by inferring accurate DNA-binding
specificities under well-defined and easily varied in vitro conditions. The experimental
protocol for DIP-chip can also be used for a rather different purpose, which is comparing the
sites of binding in vitro with the sites of binding in vivo, as defined by ChIP-chip. Comparisons
of DIP-chip and ChIP-chip experiments will be useful in determining how much of the
specificity of in vivo interactions depends on chromatin and other epigenetic factors, and how
much is inherent to the protein and DNA itself. Both PBMs and DIP-chip are powerful adjuncts
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to ChIP-chip and Dam-ID experiments, and are efficient and accurate methods for determining
in vitro DNA binding specificity.
Sequencing-based alternatives to microarray detection
The DNA purified from a ChIP experiment can be cloned and sequenced, providing an
alternative to microarray-based detection (Chen and Sadowski 2005; Impey et al. 2004; Kim
et al. 2005a; Ng et al. 2005; Roh et al. 2005; Roh et al. 2004). Currently, the cost of performing
DNA microarray hybridization on commercial arrays that cover the whole human genome is
prohibitive to all but the wealthiest labs. Even with these “whole genome” arrays, the whole
genome is not represented, only the non-repetitive portions. Therefore, sequencing-based
methods could prove to be very attractive, particularly for larger genomes. Rather than
sequencing the entire cloned DNA fragments, most of the referenced methods are similar to
SAGE, and create small (∼17–21 bp) tags from each enriched fragment. The main question
surrounding these methods is how many sequencing reads must be performed before an
adequate sampling of all enriched sequences is achieved. Consider the case in which a 20-fold
enrichment of targets is achieved by IP, and targets represent 1% of all genomic fragments. If
a sequencing approach is chosen, only ∼17% of all sequenced tags would be IP targets at all,
and for each experiment, a very large number of clones would have to be sequenced to sample
the entire IP result with sufficient coverage to confidently identify targets. This method may
become feasible by devising high-throughput schemes to increase the practical enrichment and
decrease background prior to sequencing. These may include prescreening clones for repetitive
elements, including a subtractive hybridization step, modification of the standard ChIP
experiment to include a second IP, or size selection to limit nonspecific clones and repetitive
elements (Weinmann and Farnham 2002). Another challenge of sequence-based methods
include assigning the sequence tag back to a unique position in the genome (Kim et al.
2005a). What may ultimately drive these alternatives to the forefront are future reductions in
sequencing costs. New commercially available sequencing technologies, such as massively
parallel signature sequencing (MPSS) (Brenner et al. 2000) and more recently and emulsion-
based method coupled to pyrosequencing (Margulies et al. 2005) can sequence tens of
thousands of DNA fragments simultaneously, and could be used to sample an entire ChIP. An
advantage of a sequencing-based approach is that the results obtained should be more directly
correlated with in vivo events when compared with microarray-based approaches.
New genomic techniques for understanding chromatin
New technologies and methods for understanding chromatin and epigenetics continue to
emerge. Many are based on long-trusted biochemical assays coupled to new detection
techniques. DNAse I hypersensitive sites have been a defining characteristic of “active”
chromatin for decades, and several new methods have arisen to map hypersensitive site
quantitatively and genome-wide (Dorschner et al. 2004; Sabo et al. 2004). Researchers have
also directly measured nucleosome occupancy with genomic methods. A clever alternative to
ChIP-chip was performed by digesting yeast chromatin with micrococcal nuclease, purifying
mononucleosomes, and using high-resolution tiling arrays to look for missing linker DNA
(Yuan et al. 2005). Using this method, the authors were able to obtain a very high-resolution
map of nucleosome occupancy on yeast chromosome III, which was consistent with earlier,
lower-resolution ChIP-chip studies (Bernstein et al. 2004b; Lee et al. 2004). Another group
separated mammalian chromatin with a sucrose gradient, and using microarrays with ∼1 Mb
resolution showed that the “open”, chromatin is composed of underlying DNA with a high
gene density (Gilbert et al. 2004). In a reciprocal approach, another group isolated chromatin
enriched for Histone H1 and relatively resistant to DNAse I digestion, and found an inverse
correlation between the isolated chromatin and gene expression (Weil et al. 2004).
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The least-understood aspects of chromatin, long-range interactions and nuclear domain
organization, remain enigmatic largely because few quantitative techniques exist for their
study. Fluorescence in situ hybridization studies of epigenetically-distinctive regions have
revealed differences in the resolution of sister chromatids believed to be a marker of DNA
replication timing (Greally et al. 1998; Kagotani et al. 2002; Takebayashi et al. 2005). Recently,
several new techniques have emerged that are providing insights into the higher-order
organization of chromatin (Carter et al. 2002; Dekker et al. 2002; Lebrun et al. 2003). Casolari
et al. mapped the genome-wide localization of several components of the S. cerevisiae nuclear
transport machinery, and their data suggests that the most highly transcribed genes are held
near nuclear pores at the periphery of the nucleus to facilitate rapid transport of mRNA to the
cytoplasm (Casolari et al. 2004).
ANALYSIS AND INTERPRETATION OF EPIGENOMIC DATA
An obvious prediction at this stage of development of the field of epigenomics is that our ability
to generate experimental results will shortly overwhelm our ability to manage and analyze
these complex, highly-dimensional data. Some of these problems will require standardization
of vocabularies and the definition of common data elements to allow the kind of syntactic and
semantic interoperability that allows us to integrate diverse sources of data. However, for the
purpose of this review we will focus on the more immediate need to analyze the results of
epigenomic studies.
Nucleosomal occupancy experiments and related computational analysis
While genomic DNA is generally packaged into chromatin, around functional regulatory
sequences local chromatin structure is often disrupted, making the regions accessible for
transcription factors. These regions, typically ∼250 bp in length, are hypersensitive (HS) to
DNAseI, thus can be detected throughout the genome by comparing the DNase treated to non-
treated genomic DNA using high-throughput quantitative PCR (Dorschner et al. 2004). Given
a collection of experimentally detected HS sequences and non-HS control sequences, a support
vector machine (SVM) can be trained to differentiate HS from non-HS sequences and predict
new HS sequences in the genome with 85% accuracy. In the SVM, each sequence is embedded
into a vector that contains the counts of all k-mers (k = 1 to 6) in the sequence. The SVM found
the CG-dinucleotide to be the most important sequence feature in the determination of HS, and
predicted 65% of HS sequences to be > 5 kb from the nearest transcription start site. The HS
sequences were also found to be enriched with CTCF recognition sequences, which are
signature insulator elements (Noble et al. 2005).
In another nucleosome occupancy study, differentially labeled micrococcal nuclease (MNase)-
treated and non-treated yeast genomic DNA were hybridized to microarrays with overlapping
50-mer probes tiled every 20 bp across the yeast chromosome (Yuan et al. 2005) . Nucleosome-
associated DNA is resistant to MNase digestion, whereas the nucleosome-free DNA regions
or linkers are hypersensitive. The authors constructed a hidden Markov model to look for well-
positioned nucleosomes as a run of 6–8 high-ratio probes (∼146 bp) and delocalized
nucleosomes as a run of >9 high-ratio probes (Yuan et al. 2005). The remaining regions with
runs of low-ratio probes were considered nucleosome-depleted DNA regions. The hidden
Markov model identified nucleosome-depleted regions of ∼150 bp at ∼200 bp upstream of
many ORFs. These regions are more conserved than the background genomic sequence,
include many transcription-factor binding sites, and are enriched for poly-A and poly-T.
ChIP-chip statistical analysis
Noise is inevitable in ChIP-chip experiments due to the random nature of chromatin shearing,
nonspecific binding during the immunoprecipitation step, infidelities in DNA amplification
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and labeling, and the noise intrinsic to microarray synthesis and hybridization. The means of
dealing with these problems to date have been based on performing independent experimental
replicates, although advances in molecular techniques and microarray resources are improving
our ability to define signals with confidence based on single experiments. To combine
experimental replicates, an error model first proposed by Hughes et al (Hughes et al. 2000)
was adapted to ChIP-chip experiments (Harbison et al. 2004; Lee et al. 2002; Ren et al.
2002; Simon et al. 2001). For ChIP-chip conducted on a transcription factor, a (ratio, p-value)
pair is reported for each intergenic probe. The ratio is a weighted average of ChIP over control
fold-change in the replicates, where weight is based on the fold-change and systematic error
in each replicate. The product of ratio and weight sum follows a normal distribution, so its p-
value can be calculated. A p-value of 0.001 has been often used as the threshold to call a binding
target, at which level false positive and false negative rates are estimated as 6–10% and 24%,
respectively (Lee and Young 2000). Each intergenic sequence represented on the microarray
is assigned to the gene(s) downstream of it. An intergenic region is assigned to two genes if it
lies in between two divergently transcribed genes (←→), and not assigned if it lies in between
two convergently transcribed genes (→←).
Transcription-factor motif finding
ChIP-chip experiments identify protein-DNA binding targets at a resolution of hundreds of
base pairs, but precise protein-DNA binding sites are often only 5–20 bp in length. Although
many chromatin regulators do not have sequence-specific DNA-recognition themselves, they
can be recruited to specific sequence locations in the genome by interacting with other proteins
(Cosma et al. 1999; Hampsey and Reinberg 2003). After targets of ChIP-chip against a
transcription factor or chromatin regulator are identified, biologists often proceed to use
computational tools to find enriched sequence motifs from the ChIP-targets to characterize the
precise protein-DNA binding sites. Earlier computational methods such as MEME (Bailey and
Elkan 1994; Grundy et al. 1996), AlignACE (Kurdistani et al. 2002; Roth et al. 1998), and
BioProspector (Liu et al. 2001) look for sequence motifs enriched in all the ChIP-target
sequences compared to the genome background. The DNA fragments most highly enriched by
ChIP often contain multiple binding sites for the same protein, so MDscan (Liu et al. 2002)
was developed to begin motif searches from these sequences. The insight that sequences with
more and stronger motif occurrences often have higher ChIP-enrichment values motivated
REDUCE (Bussemaker et al. 2001; Wang et al. 2002) and Motif Regressor (BenYehuda et al.
2005; Conlon et al. 2003) to find motifs whose occurrence in sequences correlate with ChIP-
enrichment ratio. Perhaps the most powerful tools are meta-motif finders such as TAMO
(Gordon et al. 2005) that combine different motif-finding algorithms to incorporate sequence
pattern enrichment, evolutionary conservation, microarray correlation, and known motif
databases to derive the most likely binding motif.
While formaldehyde is used with the belief that it stabilizes protein-DNA interactions, evidence
from 20 years ago indicates that it works in a ChIP experiment by trapping DNA when protein
constituents of chromatin cross-link (Solomon and Varshavsky 1985). However, the effect to
cause protein-protein cross-linking allows the interactions between two transcription factors
or chromatin regulators to be studied. An antibody used to immunoprecipitate one of an
interacting complex of proteins will pull down the DNA targets of both proteins, although the
indirect target might have weaker enrichment (Iyer et al. 2001). Therefore, if the ChIP targets
of two factors overlap significantly, yet the two factors are not expected to have the same DNA-
recognition properties, it is reasonable to hypothesize that the two proteins may be part of the
same complex. This has led to the discovery of interactions between Ifh1 and Rap1 (Wade et
al. 2004), and between Sum1 and Hst1 (Robert et al. 2004). Computational motif-finding can
even predict protein-interaction partners using ChIP-chip data from just a single protein. For
example, the canonical binding motifs of both the estrogen receptor (ER) and a forkhead protein
Lieb et al. Page 10













were discovered from ChIP targets of the ER (Carroll et al. 2005). Based on the motif
discoveries and the fact that forkhead protein FoxA1 is highly co-expressed with ER, the
authors predicted the interaction between ER and FoxA1, and later proved that FoxA1 is
required for ER binding (Carroll et al. 2005).
Analysis of ChIP-chip data on high-resolution tiling arrays
As reviewed above, many microarray platforms have been used to perform ChIP-chip
experiments in organisms with large genomes. For tiled arrays, two platforms are currently in
use, long oligonucleotide arrays from Nimblegen (Kim et al. 2005b), and Affymetrix 25-mer
oligonucleotide microarrays. Due to the significant probe variability and noise associated with
the Affymetrix arrays, robust analysis algorithms are required. The first method to analyze the
ChIP-chip experiments on Affymetrix tiled arrays was the non-parametric Wilcoxon rank sum
test (Bernstein et al. 2005; Cawley et al. 2004).
This method looks at probes in a sliding window of 800–1000 bp, ranks all the ChIP and control
probes together in each window by their perfect match-mismatch (PM-MM) values, and checks
whether the sum of probe ranks in the ChIPs are significantly higher than that in the controls.
To adjust for probe variability, another approach is to estimate the baseline hybridization
behavior of a probe across ChIP and control experiments from many different conditions and
laboratories (Carroll et al. 2005; Li et al. 2005). A hidden Markov model was then applied to
find regions of probes whose (PM-MM) values are much higher than the estimated baseline
behavior. Since the full-genome Affymetrix tiled arrays are still a developing platform that is
not currently commercially available, we expect many new analysis algorithms developed in
the near future.
Different statistical analysis programs are more appropriate for data derived from the
NimbleGen oligonucleotide arrays. These arrays are composed of long oligomers (50-mers)
and only perfect matches to the sequence are built on the arrays. One analysis program that
has been developed to identify binding sites from ChIP-chip data obtained from NimbleGen
arrays is based on percentile-derived thresholds and p-value determined peak widths which are
calculated according to the Waterman extension of the Erdos-Renyi Law. Due to the inherent
noise in the ChIP-chip data generated, this analysis program was used to predict peaks from
three independent array experiments and then the peaks that are present in at least two of the
three arrays are categorized as binding sites. Using very conservative thresholds and p-values,
E2F1 binding sites in HeLa cells were identified from ChIP-chip experiments. Interestingly,
between 30 and 40% of all promoters within the 30 Mb encompassing the ENCODE regions
were categorized as bound by E2F1 (Bieda et al., manuscript submitted) (Bieda et al. 2005).
The ChIP-chip technique is a very young technology at present, and there are differing opinions
on a number of experimental variables, including the appropriate experimental controls, the
optimal microarray design and hybridization conditions, whether experimental replicates will
continue to be necessary as the technology improves, and whether the same experimental
controls and data analytical techniques are appropriate for transcription factor binding and
histone modification studies. A lot of progress is expected in this field in the immediate future.
EPIGENETICS AND DISEASE
While the focus in this review has been on the basic scientific questions and techniques in
whole-genome epigenetic studies, the goal towards which researchers in this field are aiming
is the application of these techniques to the study of human disease. The two areas where most
insights have been gained are in mammalian development and in cancer biology. We focus on
these areas here, while recognizing that many other applications are being developed, including
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interesting new insights into the role of epigenetics in aging (Fraga et al. 2005) and sex-specific
regulation of autosomal genes (Sarter et al. 2005).
DNA methylation profiles in normal and abnormal development
Activation of a particular set of genes and inactivation of others underlies the differentiation
of cells and mammalian development. Many genes have what are described as tissue-dependent
and differentially-methylated regions, or T-DMRs (Shiota 2004). DNA methylation at T-
DMRs is involved in tissue-specific and developmentally-regulated gene expression. For
example, Pou5f1 (Oct4) is a member of the POU family of transcription factors, essential for
normal mammalian development (Nichols et al. 1998; Niwa et al. 2000; Okamoto et al.
1990; Rosner et al. 1990; Scholer et al. 1990). DNA methylation of the Oct4 T-DMR was
identified by RLGS and found to play a critical role in silencing of the locus (Hattori et al.
2004). The Oct4 gene has no CpG island at the transcription start site but has a relatively CG-
rich and TATA-less promoter (Okazawa et al. 1991; Sylvester and Scholer 1994). In the
placenta of DNA methyltransferase 1 (Dnmt1)-deficient mice, most CpGs were unmethylated
and Oct4 was expressed ectopically, supporting a causal role for cytosine methylation in the
regulation of this gene. Expression of Sry is also another example of DNA methylation of a T-
DMR mediating gene silencing (Nishino et al. 2004). Sry is a master gene for testis
differentiation in mammals (Koopman et al. 1991) and has a promoter region with rare CpGs.
Certain prolactin/growth hormone gene family members also have promoters with CpGs but
not enough to constitute a CpG island that are regulated by DNA methylation (Cho et al.
2001; Ngo et al. 1996). DNA methylation can therefore be involved in the in gene regulation
even when (or perhaps especially when) CpG dinucleotide density is insufficient to encode a
CpG island.
Rat sphingosine kinase 1 (Sphk1) is an example of a gene for which tissue-specific expression
is regulated by DNA methylation at a T-DMR (Imamura et al. 2001). The T-DMR is located
approximately 800 bp upstream of the first exon of Sphk1 in a 200 bp region at the 5′ edge of
a CpG island. The T-DMR of Sphk1 is conserved in the human and mouse genomes and these
T-DMRs are also targets of DNA methylation (Imamura et al. 2004). Other genes with T-DMR
in CpG islands have also been described, including the Ednrp (endothelin receptor type B)
(Pao et al. 2001), Pomc1 (proopiomelanocortin) (Newell-Price et al. 2001) and Serpinb5
(Maspin) (Futscher et al. 2002) genes. In addition, genome-wide screening identified CpG
islands that are methylated in a manner reflecting their gametic origin, leading to their being
termed germline differentially-methylated regions (gDMRs) (Strichman-Almashanu et al.
2002). These loci can be considered a further type of T-DMR occurring within CpG islands.
These loci represent the characterized subset of a much larger group of loci for which tissue-
specific methylation has been identified using RLGS. A genome-wide analysis focusing on
1,500 CpG islands and CG-rich regions identified 247 T-DMRs, which were methylated or
unmethylated depending cell- or tissue-type (Ohgane et al. 1998; Ohgane et al. 2005; Okazaki
et al. 1995; Shiota et al. 2002). The methylation profile of one cell- or tissue-type creates a
profile for a cell or tissue type that distinguishes it from other cells or tissues (Figure 1A).
Considering that there are 16,100 CpG islands in the mouse haploid genome (March 2005/
mm6 mouse genome assembly, UCSC Genome Browser, http://genome.ucsc.edu), of which
RLGS can only sample a subset, the number of T-DMRs is likely to expand with further studies,
allowing even more complex specific DNA methylation profiles. A further consequence of
these studies is to replace the old idea of universal unmethylation of CpG islands with a model
in which CpG methylation differences, even at CpG islands, mediates differences in cell states.
If the DNA methylation profile is a unique identification code for a cell (Figure 1) and is
involved in the regulation of gene expression, a change of the DNA methylation profile will
cause alteration of the properties of the cell. Cloned animals created by somatic cell nuclear
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transfer have been found to have aberrant DNA methylation profiles in every tested tissue
(Ohgane et al. 2001). As placentomegaly (placental overgrowth) is a frequently observed
phenotype of cloned animals regardless of the origin or gender of donor cells (Ogura et al.
2000;Tanaka et al. 2001;Wakayama and Yanagimachi 2001), RLGS was performed to
determine whether this specific problem reflected abnormal epigenetic regulation. A specific
pattern of aberrant DNA methylation at the Sall3 locus was found in the cloned mice exhibiting
the placentomegaly (Ohgane et al. 2004).
With advances in genome-wide techniques to study epigenetic regulation, extending beyond
cytosine methylation studies and testing more loci than allowed by RLGS, it is probable that
our ability to detect variability associated with normal development, cloning, assisted
reproductive technology and fetal exposures will be enhanced. A critical resource that will
allow multiple investigators to compare their observations will be a common database structure
allowing the DNA methylation and other epigenetic regulatory characteristics of genomic loci
to be assembled.
Epigenetics and cancer
Although epigenetic alterations are being recognized to occur in disorders of development, the
major current example of a disease state involving disordered epigenetic regulation is
carcinogenesis (Jones and Baylin 2002). Aberrant methylation of CpG islands in promoter
regions is involved in inactivation of various tumor-suppressor genes, such as RB, p16, VHL,
hMLH1, E-cadherin and BRCA1, processes that occur in a number of cancers, including colon,
bladder, stomach, liver, breast, uterine, and renal malignancies. In some cancers, such as gastric
cancers, tumor-suppressor genes are inactivated more frequently by their promoter methylation
than by mutations (Ushijima and Sasako 2004). At the same time, global genomic
hypomethylation is occurring in most cancer cells (Feinberg and Tycko 2004).
Hypomethylation can lead to genomic instability and contribute to tumor formation (Gaudet
et al. 2003). Hypomethylation of specific CpG islands causes aberrant expression of some
cancer-testis antigen genes, such as MAGE genes (De Smet et al. 1999) and can lead to loss of
imprinting (LOI) (Feinberg and Tycko 2004).
Epigenetic inactivation of MLH1 induces microsatellite instability (Kane et al. 1997), while
inactivation of CHFR induces loss of cell cycle checkpoint function (Mizuno et al. 2002). On
the other hand, some cancer cells harbor intrinsic abnormalities that induce increased rates of
de novo methylation (Ushijima et al. 2005). The increased rates lead to what has been described
as the CpG island methylator phenotype (CIMP), which was originally reported in colorectal
cancers (Toyota et al. 1999). However, there still remains a controversy over the presence of
CIMP (Yamashita et al. 2003), and a genome-wide analysis of well-characterized CpG islands
is awaited.
Factors that induce aberrant DNA methylation include aging and chronic inflammation and
possibly viral infection (Issa et al. 2001; Issa et al. 1994). Cell division is considered to be a
major factor in the induction of abnormal methylation (Velicescu et al. 2002). It has been
proposed that decreased gene expression and methylation of scattered CpG sites (“seeds of
methylation”) are involved in the induction of dense methylation of CpG islands (De Smet et
al. 2004; Song et al. 2002; Ushijima and Okochi-Takada 2005). The development of convenient
assay systems is necessary to identify individual factors that induce DNA methylation, and the
detailed molecular mechanisms for induction of aberrant methylation need to be understood.
The epigenetic alterations in cancer are now being used in cancer diagnosis and treatment
(Miyamoto and Ushijima 2005). For diagnostic purposes, aberrant DNA methylation can be
used first to detect cancer cells in biopsy or laboratory specimens and cancer-derived free DNA
in serum/plasma (Belinsky 2004; Laird 2003). Aberrant DNA methylation has an advantage
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over mutations because aberrant methylation can be detected sensitively, while targets for
diagnosis can be readily identified by a genome-wide search for differences in DNA
methylation (Ushijima 2005). Secondly, aberrant DNA methylation can be used to predict a
disease phenotype, such as prognosis, responses to chemotherapies, or occurrence of adverse
effects. Methylation of MGMT, a gene involved in repair of O6-methylguanine, is a useful
predictor of the responsiveness of tumors to alkylating agents in gliomas and diffuse large B-
cell lymphomas (Esteller and Herman 2004). The presence of CIMP in neuroblastomas is a
strong predictor of poor clinical outcome (Abe et al. 2005). Thirdly, aberrant methylation in
non-cancerous tissue has potential as a cancer risk marker. The presence of the LOI in normal
colonic mucosa and peripheral leukocytes is associated with risk of colorectal cancers (Cui et
al. 2003). An advantage of working with cytosine methylation as a diagnostic marker is that
DNA is a more stable nucleic acid than RNA and is consequently less sensitive to specimen
handling than RNA-based assays.
The plasticity of epigenetic information offers a good target for cancer therapeutics (Egger et
al. 2004). Administration of the DNA demethylating agent 5-aza-deoxycytidine (5-aza-dC) at
low doses for a prolonged period turned out to be more effective than higher doses in
hematological malignancies (Issa et al. 2004). To overcome the short half-life of 5-aza-dC, the
drug Zebularine, which can be administered orally, has been developed (Cheng et al. 2004).
Histone deacetylases (HDACs), are also well studied as targets of therapeutics (Marks et al.
2004; Yoshida et al. 2001). Various HDAC inhibitors have been developed for therapeutic
purposes, and tumor cells are known to show higher sensitivity to these agents than normal
cells for reasons that remain unclear. Phase I/II trials are now under way for solid tumors
(Marks et al. 2004).
GENOME-WIDE EPIGENETICS 2005: TOWARDS A HUMAN EPIGENOME
PROJECT
In this review, we have placed an emphasis on the technical advances in the analysis of the
epigenetic organization of the whole genome. We also highlight the need to develop means of
organization and analysis of epigenetic data. While we focused on the role of epigenetic
dysregulation in developmental abnormalities and cancer, the list of disorders to which
epigenetic abnormalities could be contributing is very large. If resources are to be used with
maximum efficiency to test how epigenetic regulation contributes to human disease, it has
become clear that investigator-initiated research will need to be complemented by the kind of
common resources that were used for the human genome project. These resources first and
foremost should address the difficulties of data management, integration and analysis. In
addition, just as technology innovation drove the human genome project, attention needs to be
paid to the development of the technologies that will allow genome-wide epigenetics studies,
especially applied to the limited numbers of cells that can be isolated to a high degree of purity
by techniques such as laser capture microscopy. The goal is simple – to define the role of
epigenetics in human disease, allowing new insights, diagnostic tests and drug targets. Current
efforts to create a coherent Human Epigenome Project include a recent workshop sponsored
by the American Association for Cancer Research (Jones and Martienssen 2005). While such
an undertaking is daunting in its complexity (Fig. 2), the goal is unquestionably worthwhile.
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DNA methylation profile of the cells. A) A given cell type has a unique pattern of DNA
methylation at genes. This number is increasing as we study more and more loci to identify all
genes regulated by DNA methylation. The methylation status of a gene is correlated with the
transcriptional state of the gene. B) DNA methylation profile of one cell type is different from
that of others and unique to the cell type, akin to an identification (ID) tag for the cell.
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A Human Epigenome Project is an inherently complex undertaking. In this review, we discuss
the multiple means by which epigenetic organization of the genome can be studied. Our
emphasis on a whole-genome approach is represented in panel (a) by the position C on the
graph – a focus on studying the whole genome as opposed to fewer loci in multiple tissues (A)
or in multiple individuals (B). The ideal situation is represented by position D – capturing
information genome-wide from many tissues and individuals. However, even this ambitious
undertaking neglects to take into account the further dimensions shown in panel (b), each
representing currently-recognized influences on epigenetic organization, and also fails to take
into account the multitude of genome-wide assays that can now be performed in each situation.
This simple diagram illustrates the complexity inherent to a comprehensive Human Epigenome
Project
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